AI-Powered Ulcerative Colitis Research

Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon and rectum. AI agents research mucosal healing, microbiome restoration, and JAK inhibitor strategies.

Standard of Care

5-ASA (mesalamine — mild-moderate), corticosteroids (flares), thiopurines (azathioprine), anti-TNF biologics, vedolizumab, tofacitinib/upadacitinib (JAK inhibitors), colectomy (curative).

Prevalence

~900,000 Americans with UC. Rising incidence in Asia and South America. Peak onset age 15–30.

Key Biomarkers

Emerging Research

FMT showing 27% remission in UC (pooled RCT data). Ozanimod (S1P modulator) approved for UC. Mirikizumab (anti-IL-23p19) showing strong mucosal healing. Combination advanced therapies (biologics + JAKi) for refractory disease. Curcumin as adjunctive therapy — meta-analyses support benefit.

Frequently Asked Questions

Can FMT cure ulcerative colitis?

Fecal microbiota transplantation has shown 27% remission rates in pooled RCT data — significantly better than placebo. Multi-donor, intensive protocols appear more effective. While not a 'cure,' it offers a microbiome restoration approach that may reduce dependence on immunosuppression. FDA regulatory pathways are evolving.

What is curcumin's role in UC?

Curcumin (1–3g daily) as adjunctive therapy reduces relapse rates and improves mucosal healing in UC. Meta-analyses of RCTs show significant benefit when added to 5-ASA therapy. Its NF-κB inhibition and anti-oxidant properties target key inflammatory pathways in UC.